Loading…
Loading…
LMDX (LumiraDx Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
LMDX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LMDX and 80,000+ other tickers.
See exactly how LMDX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LMDX and 80,000+ other tickers.
LumiraDx Limited is a prominent provider of point-of-care diagnostic solutions. Its core mission is to revolutionize community healthcare by equipping medical professionals with crucial diagnostic insights directly at the patient's side. The company develops and commercializes a sophisticated diagnostic platform, offering a diverse array of tests that deliver laboratory-grade performance directly at the point of care. With approximately 30 tests either commercially available or under development, their comprehensive portfolio addresses critical conditions such as infectious diseases…
VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- AssureCKD, a Canadian medical device company developing point-of-care solutions for chronic kidney disease (CKD) screening and diagnosis, today announced the appointment of Dr. Aman Khan as Chief Technology Officer, effective April 13, 2026. Dr. Khan brings more than 30 years of experience in diagnostics and medical technology, with a proven track record of leading platform development from concept through to global commercialization.
PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. “We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and.
LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards.
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.